The role of anti-drug antibodies in the pharmacokinetics, disposition, target engagement, and efficacy of a GITR agonist monoclonal antibody in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 356, Issue 3, 2016, Pages 574-586

  Brunn, Nicholas D ^a   Mauze, Smita ^a   Gu, Danling ^a   Wiswell, Derek ^a   Ueda, Roanna ^a   Hodges, Douglas ^a   Beebe, Amy M ^a   Zhang, Shuli ^a   Escandón, Enrique ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG ANTIBODY; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MONOCLONAL ANTIBODY DTA 1; MONOCLONAL ANTIBODY DX400; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; TNFRSF18 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATABOLISM; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; COLON CARCINOMA; CONTROLLED STUDY; DRUG DISPOSITION; DRUG TARGETING; ENGRAFTMENT; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOGENICITY; IMMUNOMODULATION; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TREATMENT DURATION; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959018183     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.229864     Document Type: Article

References (57)

1. Abramowicz D, Crusiaux A, and Goldman M (1992) Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 327:736.
2. Alvarez HM, So OY, Hsieh S, Shinsky-Bjorde N, Ma H, Song Y, Pang Y, Marian M, and Escandán E (2012) Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice. Drug Metab Dispos 40:360-373.
3. Badylak SF and Gilbert TW (2008) Immune response to biologic scaffold materials. Semin Immunol 20:109-116.
4. Baudouin V, Crusiaux A, Haddad E, Schandene L, Goldman M, Loirat C, and Abramowicz D (2003) Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 76:459-463.
5. Beck A, Wurch T, Bailly C, and Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345-352.
6. Blank CU (2014) The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol 26:204-214.
7. Bogers WMJM, Stad RK, Janssen DJ, van Rooijen N, van Es LA, and Daha MR (1991) Kupffer cell depletion in vivo results in preferential elimination of IgG aggregates and immune complexes via specific Fc receptors on rat liver endothelial cells. Clin Exp Immunol 86:328-333.
8. Bourdage JS, Cook CA, Farrington DL, Chain JS, and Konrad RJ (2007) An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods 327:10-17.
9. Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, Muller PY, Frings W, and Sims J (2010). Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2:233-255.
10. Chirino AJ, Ary ML, and Marshall SA (2004) Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9:82-90.
11. Clarke JB (2010) Mechanisms of adverse drug reactions to biologics, in Adverse Drug Reactions (Uetrecht J ed) pp 453-474, Springer Publishers, Berlin, Germany.
12. Coe D, Begom S, Addey C, White M, Dyson J, and Chai JG (2010) Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 59:1367-1377.
13. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, and Restifo NP, et al. (2006) Agonist anti-GITR antibody enhances vaccine-induced CD81 T-cell responses and tumor immunity. Cancer Res 66: 4904-4912.
14. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, and Perales MA, et al. (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5:e10436.
15. Croft M, Benedict CA, and Ware CF (2013) Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 12:147-168.
16. De Groot AS and Martin W (2009) Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 131:189-201.
17. De Groot AS and Moise L (2007) Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel 10:332-340.
18. Ganesan LP, Kim J, Wu Y, Mohanty S, Phillips GS, Birmingham DJ, Robinson JM, and Anderson CL (2012) FcgRIIb on liver sinusoidal endothelium clears small immune complexes. J Immunol 189:4981-4988.
19. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, and Weber JS, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144.
20. Hirsch HA, Pinheiro EM, Cai M, Ma Y, Sathe M, Ayers M, and McClanahan TK (2015) Molecular characterization of mouse syngeneic tumor models in response to treatment with anti-PD-1 immunotherapy. Cancer Res 75:1328-1328.
21. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, and Hassel JC, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723.
22. Kanamaru F, Youngnak P, Hashiguchi M, Nishioka T, Takahashi T, Sakaguchi S, Ishikawa I, and Azuma M (2004) Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD251 regulatory CD41 T cells. J Immunol 172: 7306-7314.
23. Kelley M, Ahene AB, Gorovits B, Kamerud J, King LE, McIntosh T, and Yang J (2013) Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J 15:646-658.
24. Kohm AP, Williams JS, and Miller SD (2004) Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD41 T cell activation and experimental autoimmune encephalomyelitis. J Immunol 172:4686-4690.
25. Li PZ, Li JZ, Li M, Gong JP, and He K (2014) An efficient method to isolate and culture mouse Kupffer cells. Immunol Lett 158:52-56.
26. Løvdal T, Andersen E, Brech A, and Berg T (2000) Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci 113:3255-3266.
27. Lu L, Xu X, Zhang B, Zhang R, Ji H, and Wang X (2014) Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med 12:36.
28. Marabelle A, Kohrt H, Caux C, and Levy R (2014) Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 20:1747-1756.
29. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, and Brody J, et al. (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123:2447-2463.
30. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, and Chen L (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7:95-106.
31. Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, and Jaffee EM, et al. (2006) OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD81 T cell tolerance to an endogenous tumor antigen. J Immunol 176:974-983.
32. Murphy JT, Burey AP, Beebe AM, Gu D, Presta LG, Merghoub T, and Wolchok JD (2014) Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood 123:2172-2180.
33. Nishikawa H, Kato T, Hirayama M, Orito Y, Sato E, Harada N, Gnjatic S, Old LJ, and Shiku H (2008) Regulatory T cell-resistant CD81 T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 68: 5948-5954.
34. Nlend MC, Desai S, Hong SJ, Anderson MB, Los GV, Hermanson GT, and Bell PA (2014) Biodistribution and clearance of non-targeted DyLight dyes in tumor-free nude mice for in vivo imaging. Cancer Res 74:4305.
35. Nocentini G and Riccardi C (2005) GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 35: 1016-1022.
36. Page DB, Postow MA, Callahan MK, Allison JP, and Wolchok JD (2014) Immune modulation in cancer with antibodies. Annu Rev Med 65:185-202.
37. Peggs KS, Quezada SA, and Allison JP (2009) Cancer immunotherapy: costimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 157:9-19.
38. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, and Martin P (2001) Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-b-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 297:1059-1066.
39. Pinheiro EM, Mangadu R, Phan UT, Cai M, Ma Y, Hirsch HA, McClanahan TK, Moniz RJ, Al-Assaad AS, and Basu S, et al. (2015) Evaluation of the antitumor activity of anti-PD-1 immunotherapy as a single agent and in combination with approved agents in preclinical tumor models. Cancer Res 75:269-269.
40. Reichert JM (2011). Antibody-based therapeutics to watch in 2011. MAbs 3:76-99.
41. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, and Camacho LH (2006) Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106:2437-2444.
42. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, and Grob JJ, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526.
43. Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, Graham MA, Geboes K, Rousselle SD, and Wagner CL (2005) Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313:578-585.
44. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, Ayroldi E, and Riccardi C (2004) GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 34:613-622.
45. Schaer DA, Murphy JT, and Wolchok JD (2012) Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 24:217-224.
46. Shankar G, Pendley C, and Stein KE (2007) A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25:555-561.
47. Shankar G, Shores E, Wagner C, and Mire-Sluis A (2006) Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 24:274-280.
48. Sugamura K, Ishii N, and Weinberg AD (2004) Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4:420-431.
49. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, and Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028.
50. Tone M, Tone Y, Adams E, Yates SF, Frewin MR, Cobbold SP, and Waldmann H (2003) Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci USA 100:15059-15064.
51. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, and Atkins MB, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
52. Werier J, Cheung AH, and Matas AJ (1991) Anaphylactic hypersensitivity reaction after repeat OKT3 treatment. Lancet 337:1351.
53. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, and Samaniego F, et al. (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:69-77.
54. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, and Reed K, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133.
55. Zeng WQ, Zhang JQ, Li Y, Yang K, Chen YP, and Liu ZJ (2013) A new method to isolate and culture rat kupffer cells. PLoS One 8:e70832.
56. Zhou P, L'italien L, Hodges D, and Schebye XM (2007) Pivotal roles of CD41 effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 179:7365-7375.
57. Zhou P, Qiu J, L'Italien L, Gu D, Hodges D, Chao CC, and Schebye XM (2010) Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. J Immunother 33:789-797.